Non-cancer risks among female breast cancer survivors: a matched cohort study in Japan
- PMID: 40206327
- PMCID: PMC11979481
- DOI: 10.1016/j.lanwpc.2025.101519
Non-cancer risks among female breast cancer survivors: a matched cohort study in Japan
Abstract
Background: The number of breast cancer (BC) survivors has increased worldwide, but the landscape of their non-cancer disease risks remains unclear, especially among Asian women.
Methods: In the JMDC claims database, which covers company employees and their family members in Japan, women aged 18-74 years with and without an incident BC were matched in a 1:4 ratio for age and entry timing to the database between January 2005 and December 2019. The risks for six cardiovascular diseases (myocardial infarction, heart failure, atrial fibrillation/flutter, ischaemic stroke, intracranial haemorrhage, and pulmonary embolism) and six non-cardiovascular diseases (major osteoporotic fractures, other fractures, gastrointestinal bleeding, urinary tract infection, infectious pneumonia, and anxiety/depression) were compared between the groups.
Findings: Comparing 24,017 BC survivors and 96,068 matched women (mean age, 50.5 years, standard deviation, 8.7 years), the incidence rates of heart failure, atrial fibrillation/flutter, and all non-cardiovascular diseases were higher in the BC survivor group. The highest adjusted hazard ratio (HR) was noted for heart failure (3.99 [95% confidence interval 2.58-6.16]), followed by gastrointestinal bleeding (3.55 [3.10-4.06]), and anxiety/depression (3.06 [2.86-3.28]). The HRs in the first year were larger than those for 1-10 years for most outcomes, whereas the HRs for fracture outcomes were larger for 1-10 years.
Interpretation: BC survivors in Japan showed an increased risk of many non-cancer diseases compared to women without BC. Most risks increased more steeply during the first year following diagnosis, whereas the risk of fractures increased later.
Funding: Competitive research funding from Pfizer Health Research Foundation in Japan.
Keywords: Bleeding; Breast cancer; Cardiovascular disease; Depression; Fracture; Infection.
© 2025 The Author(s).
Conflict of interest statement
KT has received grants from Kanzawa Medical Research Foundation and the Japan Kampo Medicines Manufacturers Association. SY has received honoraria from Pfizer Inc., AstraZeneca PLC, Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, Chugai Pharmaceutical Co., Ltd., MSD K.K., Nippon Kayaku Co., Ltd., Kyowa Kirin Co., Ltd., Sysmex Corporation, and Celltrion Healthcare Japan Co., Ltd. TS has received consultation fees from Takeda Pharmaceutical Co., Ltd. and TXP Medical Co., Ltd., and lecture fees from Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., Pfizer Inc., SAS Institute Japan Ltd., CMIC Holdings Co., Ltd., and Santen Pharmaceutical Co., Ltd. Other authors declare no competing interests.
Figures



References
-
- Sung H., Ferlay J., Siegel R.L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. - PubMed
-
- National Cancer Center Hospital Cancer Registry - 5-year Observed Survival Rates 2014-2015 (in Japanese) [Internet] https://hbcr-survival.ganjoho.jp/graph?year=2014-2015&elapsed=5&type=c09... Available from:
LinkOut - more resources
Full Text Sources